$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

$ekso Overview Financials Valuation SEC Filings Company Website

2015 Form 10-K Financial Statement

#000114420416087881 Filed on March 14, 2016

Income Statement

Concept	2015	2014 Q4	2014 Q3
Revenue	$8.661M	$1.480M	$1.588M
YoY Change	62.59%		90.46%
Cost Of Revenue	$7.482M	$930.0K	$1.108M
YoY Change	98.57%		107.86%
Gross Profit	$1.179M	$554.0K	$480.0K
YoY Change	-24.37%		59.62%
Gross Profit Margin	13.61%	37.43%	30.23%
Selling, General & Admin	$16.26M	$4.110M	$3.116M
YoY Change	12.25%		105.06%
% of Gross Profit	1379.13%	741.88%	649.17%
Research & Development	$6.480M	$1.300M	$1.096M
YoY Change	67.53%		141.85%
% of Gross Profit	549.62%	234.66%	228.33%
Depreciation & Amortization	$933.0K	$210.0K	$210.0K
YoY Change	25.23%
% of Gross Profit	79.13%	37.91%	43.75%
Operating Expenses	$22.74M	$5.410M	$4.212M
YoY Change	23.9%	54000.0%	113.51%
Operating Profit	-$21.56M	-$4.856M	-$3.732M
YoY Change	28.39%		123.21%
Interest Expense	$13.00K	$0.00	$3.000K
YoY Change	-97.01%		-98.24%
% of Operating Profit
Other Income/Expense, Net	$1.971M	-$15.30M	-$15.00K
YoY Change	-3331.15%		-24.85%
Pretax Income	-$19.92M	-$20.15M	$12.02M
YoY Change	-40.98%	201400.0%
Income Tax		$0.00	$0.00
% Of Pretax Income			0.0%
Net Earnings	-$19.59M	-$20.16M	$12.02M
YoY Change	-41.99%	201450.0%	-734.87%
Net Earnings / Revenue	-226.19%	-1361.82%	757.18%
Basic Earnings Per Share	-$1.66	-$0.23	$0.15
Diluted Earnings Per Share	-$1.83	-$0.23	-$0.04
COMMON SHARES
Basic Shares Outstanding	14.61M shares	78.61M shares	78.51M shares
Diluted Shares Outstanding	14.61M shares		83.34M shares

Balance Sheet

Concept	2015	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$19.55M	$25.19M	$7.180M
YoY Change	-22.39%
Cash & Equivalents		$25.19M	$7.176M
Short-Term Investments
Other Short-Term Assets	$2.530M	$1.940M	$1.700M
YoY Change	30.41%
Inventory	$1.060M	$622.0K	$864.4K
Prepaid Expenses
Receivables	$2.070M	$1.549M	$1.922M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$25.20M	$29.30M	$11.66M
YoY Change	-13.99%	814.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.630M	$2.102M	$1.957M
YoY Change	25.24%	33.46%
Goodwill		$0.00
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.600M	$0.00	$54.76K
YoY Change	25.6%	-100.0%
Total Long-Term Assets	$7.000M	$4.174M	$3.756M
YoY Change	67.87%	23.45%
TOTAL ASSETS
Total Short-Term Assets	$25.20M	$29.30M	$11.66M
Total Long-Term Assets	$7.000M	$4.174M	$3.756M
Total Assets	$32.20M	$33.47M	$15.42M
YoY Change	-3.79%	408.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.690M	$783.0K	$1.077M
YoY Change	244.87%	-47.77%
Accrued Expenses	$1.720M	$2.378M	$1.322M
YoY Change	3340.0%	65.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due	$80.00K	$40.00K	$40.00K
YoY Change	100.0%
Total Short-Term Liabilities	$8.620M	$6.614M	$5.896M
YoY Change	30.41%	-45.13%	58860.05%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$80.00K	$90.00K
YoY Change	-100.0%
Other Long-Term Liabilities	$14.77M	$165.0K	$15.36M
YoY Change	271.11%
Total Long-Term Liabilities	$14.77M	$165.0K	$15.45M
YoY Change	263.79%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.620M	$6.614M	$5.896M
Total Long-Term Liabilities	$14.77M	$165.0K	$15.45M
Total Liabilities	$23.39M	$10.67M	$21.34M
YoY Change	119.21%	-31.72%	213300.19%
SHAREHOLDERS EQUITY
Retained Earnings		-$71.80M	-$51.65M
YoY Change		88.79%
Common Stock		$102.0K	$78.58K
YoY Change		385.71%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.810M	$22.80M	-$5.922M
YoY Change
Total Liabilities & Shareholders Equity	$32.20M	$33.47M	$15.42M
YoY Change	-3.79%	408.41%

Cashflow Statement

Concept	2015	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	-$19.59M	-$20.16M	$12.02M
YoY Change	-41.99%	201450.0%	-734.87%
Depreciation, Depletion And Amortization	$933.0K	$210.0K	$210.0K
YoY Change	25.23%
Cash From Operating Activities	-$18.27M	-$2.710M	-$3.590M
YoY Change	21.71%
INVESTING ACTIVITIES
Capital Expenditures	$1.492M	-$570.0K	-$250.0K
YoY Change	0.34%
Acquisitions
YoY Change
Other Investing Activities		-$100.0K	$0.00
YoY Change
Cash From Investing Activities	-$1.492M	-$680.0K	-$240.0K
YoY Change	0.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$14.12M	21.40M	40.00K
YoY Change	-65.45%
NET CHANGE
Cash From Operating Activities	-$18.27M	-2.710M	-3.590M
Cash From Investing Activities	-$1.492M	-680.0K	-240.0K
Cash From Financing Activities	$14.12M	21.40M	40.00K
Net Change In Cash	-$5.637M	18.01M	-3.790M
YoY Change	-123.12%
FREE CASH FLOW
Cash From Operating Activities	-$18.27M	-$2.710M	-$3.590M
Capital Expenditures	$1.492M	-$570.0K	-$250.0K
Free Cash Flow	-$19.76M	-$2.140M	-$3.340M
YoY Change	19.79%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	19552000	USD
CY2015Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	2088000	USD
CY2014Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	1551000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	29300000	USD
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	105000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	102000	USD
CY2015Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	100094000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	94499000	USD
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91391000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71801000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	8808000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	22800000	USD
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	32198000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33474000	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4252000	USD
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2924000	USD
CY2013	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1612000	USD
CY2015	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	4409000	USD
CY2014	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	2403000	USD
CY2013	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	1690000	USD
CY2014Q4	us-gaap	Assets Assets	33474000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3412000	USD
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8619000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	783000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2378000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6614000	USD
CY2015Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4613000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	3895000	USD
CY2015Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	195000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	165000	USD
CY2015Q4	us-gaap	Liabilities Liabilities	23390000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	10674000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	25190000	USD
CY2015Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2069000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1549000	USD
CY2015Q4	us-gaap	Inventory Net InventoryNet	1056000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	622000	USD
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	436000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	388000	USD
CY2015Q4	us-gaap	Assets Current AssetsCurrent	25201000	USD
CY2015Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1885000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2625000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2102000	USD
CY2015Q4	us-gaap	Deferred Costs DeferredCosts	2502000	USD
CY2014Q4	us-gaap	Deferred Costs DeferredCosts	2017000	USD
CY2015Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	97000	USD
CY2015Q4	us-gaap	Assets Assets	32198000	USD
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2694000	USD
CY2015Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3960000	USD
CY2015Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	80000	USD
CY2014Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	41000	USD
CY2014	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7400000	USD
CY2015	us-gaap	Operating Expenses OperatingExpenses	22740000	USD
CY2014	us-gaap	Operating Expenses OperatingExpenses	18353000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-21561000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2677000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-33769000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-11887000	USD
CY2015	us-gaap	Sales Revenue Net SalesRevenueNet	8661000	USD
CY2014	us-gaap	Sales Revenue Net SalesRevenueNet	5327000	USD
CY2013	us-gaap	Sales Revenue Net SalesRevenueNet	3302000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3926000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2048000	USD
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1461000	USD
CY2015	us-gaap	Cost Of Services CostOfServices	3556000	USD
CY2014	us-gaap	Cost Of Services CostOfServices	1720000	USD
CY2013	us-gaap	Cost Of Services CostOfServices	1254000	USD
CY2015	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7482000	USD
CY2014	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3768000	USD
CY2013	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2715000	USD
CY2015	us-gaap	Gross Profit GrossProfit	1179000	USD
CY2014	us-gaap	Gross Profit GrossProfit	1559000	USD
CY2013	us-gaap	Gross Profit GrossProfit	587000	USD
CY2015	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	9258000	USD
CY2014	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	7085000	USD
CY2013	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4291000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6480000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3868000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7002000	USD
CY2013	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3913000	USD
CY2013	us-gaap	Operating Expenses OperatingExpenses	10881000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-16794000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-10294000	USD
CY2015	us-gaap	Interest Expense InterestExpense	13000	USD
CY2014	us-gaap	Interest Expense InterestExpense	435000	USD
CY2013	us-gaap	Interest Expense InterestExpense	1726000	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	11000	USD
CY2014	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
CY2013	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-45000	USD
CY2014	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-61000	USD
CY2013	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-58000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1971000	USD
CY2014	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16975000	USD
CY2013	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1593000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-19590000	USD
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.24
CY2014	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.43
CY2013	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.57
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.26
CY2014	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.43
CY2013	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.57
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102241000	shares
CY2014	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	78264000	shares
CY2013	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20977000	shares
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102265000	shares
CY2014	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78264000	shares
CY2013	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20977000	shares
CY2015	pnmd	Average Monthly Cash Burn AverageMonthlyCashBurn	1520000	USD
CY2014	pnmd	Stock Issued During Period Shares Acquisitions Previously Held StockIssuedDuringPeriodSharesAcquisitionsPreviouslyHeld	4501000	shares
CY2014	pnmd	Stock Issued During Period Shares Acquisitions New Issues StockIssuedDuringPeriodSharesAcquisitionsNewIssues	779000	shares
CY2014	pnmd	Equity Interest EquityInterest	0.068	pure
CY2014Q1	pnmd	Equity Issued During Period Units New Issues EquityIssuedDuringPeriodUnitsNewIssues	9720000	shares
CY2015	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3030000	USD
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	1.00
CY2015Q4	us-gaap	Deferred Revenue DeferredRevenue	8573000	USD
CY2014Q4	us-gaap	Deferred Revenue DeferredRevenue	7307000	USD
CY2015Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	4590000	USD
CY2014Q4	us-gaap	Deferred Costs Current And Noncurrent DeferredCostsCurrentAndNoncurrent	3568000	USD
CY2015Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1464000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1847000	USD
CY2015Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	257000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	184000	USD
CY2015Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	0	USD
CY2014Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	126000	USD
CY2015Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	164000	USD
CY2014Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	221000	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	246000	USD
CY2015Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	20000	USD
CY2015Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	226000	USD
CY2015Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	146000	USD
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	40619000	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24587000	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8944000	shares
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-24245000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-33769000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-11887000	USD
CY2015	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-2505000	USD
CY2014	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2013	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-26750000	USD
CY2014	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-33769000	USD
CY2013	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11887000	USD
CY2015	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	24000	shares
CY2014	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2013	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
CY2014Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	14410000	shares
CY2015	dei	Document Type DocumentType	10-K
CY2015	dei	Amendment Flag AmendmentFlag	false
CY2015	dei	Document Period End Date DocumentPeriodEndDate	2015-12-31
CY2015	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
CY2015	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2015	dei	Entity Registrant Name EntityRegistrantName	EKSO BIONICS HOLDINGS, INC.
CY2015	dei	Entity Central Index Key EntityCentralIndexKey	0001549084
CY2015	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2015	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2015	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2015	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2015	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2015Q2	dei	Entity Public Float EntityPublicFloat	82962801	USD
CY2015	dei	Trading Symbol TradingSymbol	PNMD
CY2016Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	108555641	shares
CY2015Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1584000	USD
CY2014Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	55000	USD
CY2015Q4	us-gaap	Goodwill Goodwill	189000	USD
CY2014	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	0	USD
CY2013	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	0	USD
CY2014Q4	us-gaap	Goodwill Goodwill	0	USD
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	13000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	13000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	105191000	shares
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	105191000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	101622000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	101622000	shares
CY2015	us-gaap	Preferred Stock Amount Of Preferred Dividends In Arrears PreferredStockAmountOfPreferredDividendsInArrears	4655000	USD
CY2015	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Use of Estimates</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to: revenue recognition, deferred revenue and the deferral of associated costs, valuation of acquired intangible assets and goodwill, useful lives assigned to long-lived assets, realizability of deferred tax assets, valuation of common and preferred stock warrants, the valuation of options, and contingencies. Actual results could differ from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Concentration of Credit Risk and Other Risks and Uncertainties</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Financial instruments that potentially subject us to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains our cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.  The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Accounts receivable are derived from the sale of products shipped and services performed for customers located in the U.S. and throughout the world. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provide an allowance for credit losses, as needed. The Company has not experienced material losses related to accounts receivable as of December 31, 2015 and December 31, 2014. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and are susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling foreign contracts.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In 2015, the Company had one customer with accounts receivable balances totaling 10% or more of the Company’s total accounts receivable (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>%) compared with two customers in 2014 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">22</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11</font>%).</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">In 2015, the Company had one customer with billed revenue of 10% or more of the Company’s total customer revenue (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33</font>%), compared with one customer in 2014 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12</font>%) and two customers in 2013 (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 10</font>%).</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015	us-gaap	Derivatives Embedded Derivatives DerivativesEmbeddedDerivatives	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><strong>Common Stock Warrant Liability</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">For warrants where there is a possibility that we may have to settle the warrants in cash, or for warrants with price-based anti dilution features, we record the fair value of the issued warrants as a liability at each reporting date and records changes in the estimated fair value as a non-cash gain or loss in the consolidated statements of operations. The fair values of these warrants have been determined using the Binomial Lattice (“Lattice”) valuation model, and the changes in the fair value are recorded in the consolidated statements of operations. The Lattice model provides for assumptions regarding volatility, call and put features and risk-free interest rates within the total period to maturity. These values are subject to a significant degree of judgment on our part.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	48000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	19590000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	33769000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	11887000	USD
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4878000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3604000	USD
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2253000	USD
CY2014Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	78264000	shares
CY2015Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	783000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	554000	USD
CY2015Q4	us-gaap	Inventory Gross InventoryGross	1138000	USD
CY2014Q4	us-gaap	Inventory Gross InventoryGross	670000	USD
CY2015Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	82000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1502000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	933000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	745000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	469000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-19918000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-33750000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-11928000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	328000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	113000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	65000	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-19590000	USD
CY2014	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-33637000	USD
CY2013	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-11863000	USD
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.340	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.015	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.058	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.005	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.003	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.384	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.189	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.401	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.010	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.002	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.036	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.005	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.001	pure
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001	pure
CY2014	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.001	pure
CY2013	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.016	pure
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2014	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2013	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0	pure
CY2015Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	1409000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26826000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19525000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	530000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	381000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	29298000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21315000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	317000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	693000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1222000	USD
CY2015Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	43000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	220000	USD
CY2015Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	113000	USD
CY2015	us-gaap	Open Tax Year OpenTaxYear	2007
CY2015Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	13743000	shares
CY2015	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P7Y9M11D
CY2015Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1	1.01
CY2015Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions	6308000	shares
CY2015Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.70
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1731000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1143000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	391000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0141	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0097	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0083	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0250	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0261	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0193	pure
CY2014	us-gaap	Advertising Expense AdvertisingExpense	1000	USD
CY2015Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.05	pure
CY2013Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	2.10
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7321	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.66	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.65	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.7567	pure
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.75	pure
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.71	pure
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1089000	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Two LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearTwo	90000	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Three LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearThree	60000	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Four LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFour	37000	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Year Five LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearFive	37000	USD
CY2015Q4	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal After Year Five LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalAfterYearFive	22000	USD
CY2015	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	342000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	343000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	339000	USD
CY2015Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	9195000	USD
CY2014Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	0	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	768000	USD
CY2014Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	0	USD
CY2015Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	93000	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	55000	USD
CY2015	pnmd	Warrant Issuance Expense WarrantIssuanceExpense	487000	USD
CY2014	pnmd	Warrant Issuance Expense WarrantIssuanceExpense	0	USD
CY2013	pnmd	Warrant Issuance Expense WarrantIssuanceExpense	0	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-25087000	USD
CY2013	pnmd	Adjustments To Additional Paid In Capital Warrant Issued Adjustment AdjustmentsToAdditionalPaidInCapitalWarrantIssuedAdjustment	136000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	65000	USD
CY2013	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	0	USD
CY2013	pnmd	Adjustments To Additional Paid In Capital Vesting Of Early Exercised Options AdjustmentsToAdditionalPaidInCapitalVestingOfEarlyExercisedOptions	4000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	396000	USD
CY2013	us-gaap	Stockholders Equity Note Spinoff Transaction StockholdersEquityNoteSpinoffTransaction	0	USD
CY2013	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	0	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-36373000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	-8765000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	6813000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	282000	USD
CY2014Q1	pnmd	Stock Issued During Period Value Conversion Of Convertible Preferred Stock StockIssuedDuringPeriodValueConversionOfConvertiblePreferredStock	27324000	USD
CY2014Q1	pnmd	Stock Issued During Period Value Private Placement Offering StockIssuedDuringPeriodValuePrivatePlacementOffering	25300000	USD
CY2014Q1	pnmd	Private Placement Offering Stock Issued During Period Value Conversion Of Debt PrivatePlacementOfferingStockIssuedDuringPeriodValueConversionOfDebt	5082000	USD
CY2014Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	USD
CY2014Q1	pnmd	Adjustments To Additional Paid In Capital Fair Value Of Warrant Obligation Transferred To Equity AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantObligationTransferredToEquity	96000	USD
CY2014Q1	pnmd	Adjustments To Additional Paid In Capital Decrease Due To Unamortized Debt Discounts Transferred To Equity AdjustmentsToAdditionalPaidInCapitalDecreaseDueToUnamortizedDebtDiscountsTransferredToEquity	947000	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	3339000	USD
CY2014Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	10614000	USD
	pnmd	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	21412000	USD
	pnmd	Adjustments To Additional Paid In Capital Fair Value Of Warrant Liability Transferred To Equity Upon Removal Of Antidilution Clause AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrantLiabilityTransferredToEquityUponRemovalOfAntidilutionClause	27099000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	102000	USD
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1143000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-33769000	USD
CY2015	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.33	pure
CY2015	us-gaap	Advertising Expense AdvertisingExpense	25000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-9063000	USD
CY2013	us-gaap	Advertising Expense AdvertisingExpense	6000	USD
CY2015	us-gaap	Depreciation Depreciation	933000	USD
CY2014	us-gaap	Depreciation Depreciation	745000	USD
CY2013	us-gaap	Depreciation Depreciation	469000	USD
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	34000	USD
CY2014	us-gaap	Inventory Write Down InventoryWriteDown	-36000	USD
CY2013	us-gaap	Inventory Write Down InventoryWriteDown	-8000	USD
CY2015	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	-37000	USD
CY2014	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	-36000	USD
CY2013	us-gaap	Amortization Of Deferred Charges AmortizationOfDeferredCharges	-36000	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2014	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	208000	USD
CY2013	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	169000	USD
CY2015	us-gaap	Accretion Expense AccretionExpense	0	USD
CY2014	us-gaap	Accretion Expense AccretionExpense	20000	USD
CY2013	us-gaap	Accretion Expense AccretionExpense	231000	USD
CY2015	us-gaap	Interest Income Other InterestIncomeOther	0	USD
CY2014	us-gaap	Interest Income Other InterestIncomeOther	-3000	USD
CY2013	us-gaap	Interest Income Other InterestIncomeOther	0	USD
CY2015	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2014	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	0	USD
CY2013	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	-799000	USD
CY2015	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	21000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	1731000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	1143000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	391000	USD
CY2015	pnmd	Gain Loss On Warrant Liability GainLossOnWarrantLiability	2505000	USD
CY2014	pnmd	Gain Loss On Warrant Liability GainLossOnWarrantLiability	-16485000	USD
CY2013	pnmd	Gain Loss On Warrant Liability GainLossOnWarrantLiability	186000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	520000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1000000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-239000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	200000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-354000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	102000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	91000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	36000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	87000	USD
CY2015	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	1022000	USD
CY2014	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	1995000	USD
CY2013	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	442000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1738000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-716000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-231000	USD
CY2015	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-493000	USD
CY2014	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	944000	USD
CY2013	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	433000	USD
CY2015	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1266000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2679000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1164000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-18269000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-15007000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1492000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1487000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	379000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1492000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1487000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-379000	USD
CY2015	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2014	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	USD
CY2013	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2000000	USD
CY2015	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2013	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4929000	USD
CY2015	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2014	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2013	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	948000	USD
CY2015	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	13906000	USD
CY2014	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	0	USD
CY2013	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	4152000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	225000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	102000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	205000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5638000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	24385000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-933000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	805000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1738000	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	12000	USD
CY2014	us-gaap	Income Taxes Paid IncomeTaxesPaid	138000	USD
CY2013	us-gaap	Income Taxes Paid IncomeTaxesPaid	633000	USD
CY2015	us-gaap	Interest Paid InterestPaid	5000	USD
CY2014	us-gaap	Interest Paid InterestPaid	38000	USD
CY2013	us-gaap	Interest Paid InterestPaid	25000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	14123000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	40879000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	8509000	USD
CY2015Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	40000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	1610000	USD
CY2015	pnmd	Acquisitionofpropertyandequipmentwithcapitallease Acquisitionofpropertyandequipmentwithcapitallease	166000	USD
CY2014	pnmd	Acquisitionofpropertyandequipmentwithcapitallease Acquisitionofpropertyandequipmentwithcapitallease	0	USD
CY2013	pnmd	Acquisitionofpropertyandequipmentwithcapitallease Acquisitionofpropertyandequipmentwithcapitallease	0	USD
CY2015	pnmd	Beneficial Conversion Feature On Issuance Of Preferred Stock BeneficialConversionFeatureOnIssuanceOfPreferredStock	4655000	USD
CY2014	pnmd	Beneficial Conversion Feature On Issuance Of Preferred Stock BeneficialConversionFeatureOnIssuanceOfPreferredStock	0	USD
CY2013	pnmd	Beneficial Conversion Feature On Issuance Of Preferred Stock BeneficialConversionFeatureOnIssuanceOfPreferredStock	0	USD
CY2015	pnmd	Issuance Of Preferred Stock Warrants IssuanceOfPreferredStockWarrants	11700000	USD
CY2014	pnmd	Issuance Of Preferred Stock Warrants IssuanceOfPreferredStockWarrants	0	USD
CY2013	pnmd	Issuance Of Preferred Stock Warrants IssuanceOfPreferredStockWarrants	0	USD
CY2015	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	1839000	USD
CY2014	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2013	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2015	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2014	us-gaap	Stock Issued1 StockIssued1	0	USD
CY2013	us-gaap	Stock Issued1 StockIssued1	5000	USD
CY2015	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2014	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	0	USD
CY2013	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	6490000	USD
CY2015	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2014	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	0	USD
CY2013	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	169000	USD
CY2015	pnmd	Conversionofbridgeloantocommonstock Conversionofbridgeloantocommonstock	0	USD
CY2014	pnmd	Conversionofbridgeloantocommonstock Conversionofbridgeloantocommonstock	5082000	USD
CY2013	pnmd	Conversionofbridgeloantocommonstock Conversionofbridgeloantocommonstock	0	USD
CY2015	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2014	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	27324000	USD
CY2013	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
CY2015	pnmd	Conversionofpreferredstockwarrantstocommonstockwarrants Conversionofpreferredstockwarrantstocommonstockwarrants	0	USD
CY2014	pnmd	Conversionofpreferredstockwarrantstocommonstockwarrants Conversionofpreferredstockwarrantstocommonstockwarrants	282000	USD
CY2013	pnmd	Conversionofpreferredstockwarrantstocommonstockwarrants Conversionofpreferredstockwarrantstocommonstockwarrants	0	USD
CY2015	pnmd	Transferofwarrantliabilitytoequity Transferofwarrantliabilitytoequity	0	USD
CY2014	pnmd	Transferofwarrantliabilitytoequity Transferofwarrantliabilitytoequity	27099000	USD
CY2013	pnmd	Transferofwarrantliabilitytoequity Transferofwarrantliabilitytoequity	0	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	0	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	0	USD
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost	5000	USD
CY2015	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	60000	USD
CY2014	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2596000	USD
CY2013	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1829000	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	52000	USD
CY2014	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	21412000	USD
CY2013	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21961000	USD
CY2015Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	1650000	USD
CY2015Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	1839000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	1197000	USD
CY2015Q4	pnmd	Description Of Warrants And Preferred Shares DescriptionOfWarrantsAndPreferredShares	The Preferred Shares and Warrants were sold in units, with each unit consisting of one Preferred Share and a Warrant to purchase up to 0.9901 shares of Common Stock.
CY2015Q4	us-gaap	Notes Receivable Net NotesReceivableNet	101000	USD
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	2915000	USD
CY2015Q4	us-gaap	Sales Revenue Net SalesRevenueNet	1943000	USD
CY2014Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1062000	USD
CY2014Q3	us-gaap	Sales Revenue Net SalesRevenueNet	1588000	USD
CY2014Q4	us-gaap	Sales Revenue Net SalesRevenueNet	1480000	USD
CY2015	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	9434000	USD
CY2014	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	5449000	USD
CY2015	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-19590000	USD
CY2014	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-33978000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26000	USD
CY2015	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value High BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueHigh	1750000	USD
CY2015	us-gaap	Business Combination Contingent Consideration Arrangements Change In The Range Of Outcomes Contingent Consideration Liability Value Low BusinessCombinationContingentConsiderationArrangementsChangeInTheRangeOfOutcomesContingentConsiderationLiabilityValueLow	3000000	USD
CY2015	pnmd	Expiration Date Of Buyout Payment Provision ExpirationDateOfBuyoutPaymentProvision	2017-11-30
CY2015	us-gaap	Fair Value Inputs Discount Rate FairValueInputsDiscountRate	0.15	pure
CY2015	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P3Y
CY2015	us-gaap	Business Combination Consideration Transferred Other1 BusinessCombinationConsiderationTransferredOther1	1071000	USD
CY2015	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	1839000	USD
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2013	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	USD
CY2015Q4	pnmd	Preferred Shares And Warrants Purchase Price PreferredSharesAndWarrantsPurchasePrice	1000000	USD
CY2015Q4	pnmd	Gross Proceeds From Preferred Stock And Warrants GrossProceedsFromPreferredStockAndWarrants	15000000	USD
CY2015Q4	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	13906000	USD
CY2015Q4	pnmd	Stock Related Expenses Payable StockRelatedExpensesPayable	173000	USD
CY2015Q4	pnmd	Minimum Percentage Of Vote Holders Of Preferred Stock MinimumPercentageOfVoteHoldersOfPreferredStock	0.75	pure
CY2015Q4	pnmd	Preferred Stock Converted Into Common Stock PreferredStockConvertedIntoCommonStock	3300000	shares
CY2015Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.01
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	13796000	shares
CY2015Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	14851000	shares
CY2015	pnmd	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	-52000	shares
CY2015Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	28595000	shares
CY2015	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7983000	USD
CY2014	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	6371000	USD
CY2015	pnmd	Stock Issued During Period Shares Conversion Of Convertible Preferred Stock StockIssuedDuringPeriodSharesConversionOfConvertiblePreferredStock	2000	shares
CY2015	pnmd	Stock Conversion Price Per Share StockConversionPricePerShare	1.01
CY2015Q4	us-gaap	Area Of Land AreaOfLand	4585	acre
CY2015	us-gaap	Lessee Leasing Arrangements Operating Leases Term Of Contract LesseeLeasingArrangementsOperatingLeasesTermOfContract	P5Y
CY2015	us-gaap	Lessee Leasing Arrangements Operating Leases Renewal Term LesseeLeasingArrangementsOperatingLeasesRenewalTerm	P5Y
CY2015Q1	us-gaap	Sales Revenue Net SalesRevenueNet	1689000	USD
CY2015Q2	us-gaap	Sales Revenue Net SalesRevenueNet	2114000	USD
CY2015Q1	us-gaap	Gross Profit GrossProfit	403000	USD
CY2015Q2	us-gaap	Gross Profit GrossProfit	502000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	468000	USD
CY2015Q4	us-gaap	Gross Profit GrossProfit	-194000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	480000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	45000	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	480000	USD
CY2014Q4	us-gaap	Gross Profit GrossProfit	554000	USD
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-81766000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	56128000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	12024000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-20155000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.22
CY2014Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.72
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
CY2014Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2014Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.22
CY2014Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2014Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
CY2015Q4	pnmd	Maximum Financing In Anti Dilution Provision MaximumFinancingInAntiDilutionProvision	10000000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	225000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1731000	USD
CY2015	pnmd	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	52000	USD
CY2015	pnmd	Convertible Preferred Stock Beneficial Conversion Feature ConvertiblePreferredStockBeneficialConversionFeature	4655000	USD
CY2015	us-gaap	Stock Issued During Period Value Purchase Of Assets StockIssuedDuringPeriodValuePurchaseOfAssets	1071000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14218000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	3300000	USD
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-4115000	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-5645000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-5185000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-4645000	USD
CY2015Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4115000	USD
CY2015Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5645000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5185000	USD
CY2015Q4	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9300000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	0	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	199000	USD
CY2015Q4	us-gaap	Contractual Obligation ContractualObligation	1344000	USD
CY2015Q4	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	704000	USD
CY2015Q4	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	298000	USD
CY2015Q4	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	119000	USD
CY2015Q4	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	119000	USD
CY2015Q4	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	104000	USD
CY2015Q4	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	50000	USD
CY2015	pnmd	Supply Agreement Minimum Annual Price SupplyAgreementMinimumAnnualPrice	157000	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value Low BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueLow	157000	USD
CY2015Q4	us-gaap	Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh	521000	USD
CY2015	pnmd	Effective Income Tax Rate Reconciliation Unrealized Gain Loss On Warrant EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant	0.043	pure
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	0	USD
CY2015Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	336000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	53000	USD
CY2015Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	19000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	63000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3311000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	11590000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	4705000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	232000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	114000	shares
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	10542000	shares
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2505000	USD
CY2015Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	11700000	USD
CY2013Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	93000	USD
CY2014Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	143000	USD
CY2014	pnmd	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	4000	USD
CY2015	pnmd	Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions	-19000	USD
CY2014	pnmd	Unrecognized Tax Benefits Increases Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromCurrentPeriodTaxPositions	46000	USD
CY2015	pnmd	Unrecognized Tax Benefits Increases Decreases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromCurrentPeriodTaxPositions	75000	USD
CY2015	pnmd	Adjustments To Additional Paid In Capital Issuance Of Warrants AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrants	-11700000	USD
CY2015	pnmd	Stock Issued During Period Value Conversion Of Preferred Stock To Common Stock And Accretion Of Preferred Discount StockIssuedDuringPeriodValueConversionOfPreferredStockToCommonStockAndAccretionOfPreferredDiscount	1356000	USD
CY2015	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	782000	USD
CY2015Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare

Files In Submission

Name	View Source	Status
0001144204-16-087881-index-headers.html	Edgar Link	pending
0001144204-16-087881-index.html	Edgar Link	pending
0001144204-16-087881.txt	Edgar Link	pending
0001144204-16-087881-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pnmd-20151231.xml	Edgar Link	completed
pnmd-20151231.xsd	Edgar Link	pending
pnmd-20151231_cal.xml	Edgar Link	unprocessable
pnmd-20151231_def.xml	Edgar Link	unprocessable
pnmd-20151231_lab.xml	Edgar Link	unprocessable
pnmd-20151231_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tlogoex10-36.jpg	Edgar Link	pending
tpg40.jpg	Edgar Link	pending
v432273_10k.htm	Edgar Link	pending
v432273_ex10-36.htm	Edgar Link	pending
v432273_ex21-1.htm	Edgar Link	pending
v432273_ex23-1.htm	Edgar Link	pending
v432273_ex31-1.htm	Edgar Link	pending
v432273_ex31-2.htm	Edgar Link	pending
v432273_ex32-1.htm	Edgar Link	pending
v432273_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso

2015 Form 10-K Financial Statement

#000114420416087881 Filed on March 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO EKSO BIONICS HOLDINGS, INC. Stock $ekso

2015 Form 10-K Financial Statement

#000114420416087881 Filed on March 14, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EKSO
EKSO BIONICS HOLDINGS, INC. Stock $ekso